Divestiture/carve-outAug 27, 2026Pending
🇺🇸 United States
BTBioXcel Therapeutics, Inc.TPTeva Pharmaceutical Industries Limited
Healthcare › Pharmaceuticals
Deal valueUndisclosed
AnnouncedAug 27, 2026
ConsiderationCash
StructureOther
RegionNorth America
Cross-borderUnknown
Contingent paymentNo
Overview
Teva Pharmaceutical Industries Limited agreed to acquire substantially all of the assets of BioXcel Therapeutics, Inc. and its subsidiaries OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC for an undisclosed cash price.
Deal rationale
The sellers are seeking to sell substantially all of their assets through a Chapter 11 process.
AI-generated from the SEC filingPendingHealthcare › PharmaceuticalsUnited StatesNorth America
Timeline
Valuation and terms
| Equity value | Undisclosed | |
|---|---|---|
| Enterprise value | Undisclosed | |
| Consideration | Cash |
Advisors
Buy-side
GSGuggenheim Securities
Sell-side
MHMTS Health Partners
Parties
Target
BTBioXcel Therapeutics, Inc.
- Headquarters
- United States
- Ticker
- —
Acquirer
TPTeva Pharmaceutical Industries Limited
- Headquarters
- —
- Ticker
- —
Seller
BTBioXcel Therapeutics, Inc., OnkosXcel Therapeutics, LLC, OnkosXcel Employee Holdings, LLC
- Headquarters
- —
- Ticker
- —